Looking Backward, Looking Forward
I believe it is fair to say that 2016 was a bit unusual. Thinking about the terminology many of us learned last year leads us to that conclusion: snowflake,…
Menu
On Catamarans, Elections, and #BIOEurope
BIO Europe was, yet again, an excellent conference for Lacerta Bio. Having the US election on television screens in the Exhibition Hall made for some surreal moments and discussions. Not a…
University Technology Transfer: Change is Needed
A few weeks ago, we attended the first annual Commercializing Biotech Innovation Conference in Syracuse, New York. The conference was held in the very new Central New York Biotech Accelerator in Syracuse (which is…
HIV/AIDS: Growing Unmet Need & Declining Interest?
In our last post, we presented a model which helps us aggregate a series of variables which, in turn, help us understand why certain therapeutic areas or indications are of greater interest from a licensing perspective than others.
Our aim with this model is to help companies with licenseable assets to frame their “stories” in a way which is compatible with how potential partners approach evaluation and decision-making.
Our first attempt at applying this model is for the HIV/AIDS market. During the 1990s, stories about AIDS were a daily occurrence on the nightly news. Images of celebrities fighting and dying from AIDS seemed to be everywhere. Rock Hudson, Freddy Mercury, Anthony Perkins…the list of celebrities who succumbed to complications from this disease seemed endless.
But what about today? Are there Unmet Needs which can be satisfied via novel therapeutics? And, if so, are they being funded and developed? Are there multinational companies with a stated interested in licensing these innovations once they are sufficiently mature?
In this post, we take a look at these questions.
On Triumvirates and Licensing
A triumvirate is a three-person (or three-group) organization which is established for a specific administrative task(s). In Ancient Rome, the First Triumvirate was established between Julius Caesar, Pompey the…
Can Precision Medicine Help Fight Alzheimer’s Disease?
There is an interesting article in the current issue of The Journal of Precision Medicine on Alzheimer's. The article attempts to answer a seemingly simple, yet complex question...Can systems biology…
The Age of Virtual Pharma: Creative Financing and Exit Models
At last month's Biotech Showcase, a panel discussion was held discussing different models for advancing assets without resorting to a license. The link to the discussion is here. It…
Has Pharma Forgotten about HIV?
Nearly 30 years ago, back when your author was a humble pharmacy intern, the first therapeutic to combat HIV (azidothymidine) was introduced by Burroughs Wellcome (now part of GSK). Back…
Looking Forward to 2016
Given that we are now in January, we feel obliged to craft some sort of "Predictions for 2016" post. We're not big fans of predictive posts, mainly because we're…
#BEU15 Wrap Up: Churches, Football, and Meetings
I love what you did with the place... It's always difficult for us to contribute any sensible overarching overview of any partnering conference, especially BIO Europe Fall. This is entirely…